• 
  Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
• 
  Thomas Kaley, Mehdi Touat, Vivek Subbiah, Antoine Hollebecque, Jordi Rodon, et al.. BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36 (35), pp.3477-3484. ⟨10.1200/JCO.2018.78.9990⟩. ⟨hal-04541090⟩
• 
  Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.298. ⟨10.1186/s13063-023-07294-0⟩. ⟨hal-04176626⟩
• 
  Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petite cellules avec translocation ALK en France. Étude BRIGALK.. Congrès de pneumologie de langue française, Jan 2019, Marseille, France. ⟨10.1016/j.rmr.2018.10.039⟩. ⟨hal-02633916⟩
• 
  Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer, 2019, 136, pp.109-114. ⟨10.1016/j.lungcan.2019.08.010⟩. ⟨hal-04529929⟩
• 
  Dana M Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.452. ⟨10.1186/s13063-023-07467-x⟩. ⟨inserm-04526673⟩
• 
  Thi-Van-Trinh Tran, Carole Rubino, Rodrigue Allodji, Milena Andruccioli, Stéphane Bardet, et al.. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. British Journal of Cancer, 2022, 127 (12), pp.2118-2124. ⟨10.1038/s41416-022-01982-5⟩. ⟨inserm-04438463⟩
• 
  P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
• 
  M Tonneau, R Nebbache, A Larnaudie, S Thureau, Y Pointreau, et al.. Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: Role of locoregional radiotherapy and metastasis-directed radiotherapy. Cancer/Radiothérapie, 2024, 28 (1), pp.83-92. ⟨10.1016/j.canrad.2023.03.004⟩. ⟨hal-04441453⟩
• 
  Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault de La Motte Rouge, Thierry Petit, et al.. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast Cancer Research and Treatment, 2024, ⟨10.1007/s10549-024-07285-y⟩. ⟨hal-04495069⟩

175

206